Evidence that the p2y3 Receptor Is the Avian Homologue of the Mammalian P2Y6 Receptor

  1. Qing Li,
  2. Melanie Olesky,
  3. R. Kyle Palmer,
  4. T. Kendall Harden and
  5. Robert A. Nicholas
  1. Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7365
     
    Next Section

    Abstract

    A P2Y receptor with 65% identity to mammalian P2Y6receptors, termed the p2y3 receptor, was recently cloned from a chick brain cDNA library and was proposed to represent a novel P2Y receptor subtype [Mol Pharmacol50:258–265 (1996)]. We cloned the turkey homologue of the chick p2y3 receptor, which shares high sequence identity (97.6%) with the chick receptor, and we stably expressed this receptor and the rat P2Y6 receptor in 1321N1 human astrocytoma cells. The capacities of uridine and adenine nucleotides to promote inositol phosphate accumulation and intracellular Ca2+ mobilization were determined for both receptors. UDP and 5-bromo-UDP were the most potent agonists and UTP was a less potent full agonist at both receptors. In contrast, adenine nucleotides and nucleotide derivatives were relatively more potent at the turkey p2y3 receptor than at the rat P2Y6 receptor. To determine whether the avian p2y3 receptor defined a new subtype of mammalian P2Y receptor or was a species homologue of the mammalian P2Y6 receptor, we screened two different human genomic libraries and a Southern blot with a p2y3 receptor probe, under low-stringency conditions that allowed the clear identification of the human P2Y6 receptor gene. Our data indicated that the human genome does not contain a receptor that is more homologous to the avian p2y3 receptor than the P2Y6 receptor. Taken together, these data further define the pharmacological selectivities of these UDP-selective receptors and strongly suggest that the avian p2y3 receptor is a species homologue of the mammalian P2Y6receptor.

    P2Y receptors are G protein-coupled receptors that mediate a wide variety of physiological effects in response to extracellular adenine and uridine nucleotides (Harden et al., 1995; Filtz et al., 1997). Although the existence of multiple subtypes of P2Y receptors was evident from early pharmacological studies, the application of molecular cloning and expression of P2Y receptors has provided a better understanding of this family of nucleotide receptors. Eleven different G protein-coupled receptors (termed P2Y1 through P2Y11) have been claimed to be members of the P2Y receptor family, but only five of these receptors (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11) have been cloned from mammalian species and shown unambiguously to mediate nucleotide-promoted second messenger responses. The P2Y1 receptor is activated specifically by adenine nucleotides, with ADP being more potent than ATP (Hendersonet al., 1995; Schachter et al., 1996), although recent studies have suggested that ATP and ATP derivatives are antagonists at the P2Y1 receptor (Leon et al., 1997; Hechler et al., 1998). The P2Y2 receptor is activated equipotently by ATP and UTP (Parr et al., 1994), the P2Y4receptor is activated only by UTP (Nguyen et al., 1995;Communi et al., 1996; Lazarowski et al., 1997), the P2Y6 receptor is activated selectively by UDP (Nicholas et al., 1996), and the P2Y11receptor is activated primarily by ATP (Communi et al.,1997). All of these receptors activate PLC. In addition to coupling to PLC, the P2Y11 receptor has been reported to activate adenylyl cyclase (Communi et al., 1997).

    The cloning from a chick brain cDNA library and characterization of an additional P2Y receptor, termed the p2y3 receptor,1 was reported recently (Webb et al., 1996). The p2y3 receptor is 65% identical to the rat P2Y6 receptor and 38, 42, and 41% identical to human P2Y1, P2Y2, and P2Y4 receptors, respectively. The nucleotide selectivity and second messenger signaling properties of the p2y3 receptor have not been completely defined. In studies measuring the amplitudes of Ca2+-activated Cl−currents in p2y3 receptor-expressing Xenopus laevis oocytes, ADP (100 μm) elicited the largest current, followed by ATP-γ-thiol, UTP, ATP, and UDP. In contrast, UDP was the most potent agonist, followed by UTP, ADP, ATP-γ-thiol, and ATP, in measurements of intracellular Ca2+ mobilization in p2y3 receptor-expressing Jurkat cells. Although it is likely that the mobilization of intracellular Ca2+ was a consequence of activation of PLC and production of inositol-1,4,5-trisphosphate, no direct analysis of inositol lipid hydrolysis was reported.

    Webb et al. (1996) proposed that the chick p2y3 receptor is a unique subtype of P2Y receptor. However, given the similarities in both sequence identity and apparent nucleoside diphosphate selectivity of the chick p2y3 receptor and the rat P2Y6receptor, it is conceivable that the p2y3 receptor is the avian homologue of the previously reported mammalian P2Y6 receptor. To distinguish between these two possibilities and to directly compare the signaling properties of these two receptors, we have expressed both the turkey p2y3 receptor and the rat P2Y6 receptor in 1321N1 cells and have determined their agonist selectivities and second messenger signaling properties under identical conditions. In addition, we have screened at low stringency two human genomic libraries and a Southern blot with a turkey p2y3 probe, to identify a possible human homologue. Our results indicate that mammalian P2Y6 and avian p2y3 receptors both activate PLC and that the receptors have similar but not identical agonist selectivities. Moreover, no receptor apparently exists in the human genome with greater homology to the avian p2y3 receptor than the human P2Y6 receptor. We conclude from these data that the chick p2y3 receptor is the avian homologue of the mammalian P2Y6 receptor.

    Previous SectionNext Section

    Experimental Procedures

    Materials.

    ATP, ADP, UTP, and UDP were purchased from Pharmacia (Piscataway, NJ). The purity of these nucleotides was estimated to be >99% by HPLC analysis. 2-Methylthio-ATP, 2-methylthio-ADP, and ADP-β-thiol were purchased from Research Biochemicals (Natick, MA). 5-Bromo-UTP was from Sigma Chemical Co. (St. Louis, MO), and 5-bromo-UDP was synthesized by incubating 5-bromo-UTP with hexokinase and glucose (Lazarowski et al., 1996).myo-[3H]Inositol was from American Radiolabeled Chemicals (St. Louis, MO). [α-32P]dATP was from New England Nuclear. Hexokinase was from Sigma. All tissue culture reagents were from the tissue culture facility at the Lineberger Comprehensive Cancer Center (University of North Carolina).

    Cloning and expression of the turkey p2y3 receptor.

    Because of the similarity between chick and turkey genes, the turkey p2y3 receptor was amplified from turkey genomic DNA by PCR with primers based on the published chick p2y3 receptor sequence (Filtz et al., 1994; Webb et al., 1996). The upstream and downstream oligonucleotides were 5′-GAGACTCGAGCCACCATGAGCATGGCCAACTTCACGGG-3′ (complementary to bases 1–23 of the chick p2y3 receptor coding sequence, with the ATG codon in bold type) and 5′-GAGAGGATCCCATCCCCATCTCCGCACCATG-3′ (complementary to bases 60–81 downstream of the stop codon of the chick p2y3 receptor coding sequence), respectively. The entire coding sequence of the turkey p2y3 receptor was amplified from 1 μg of turkey genomic DNA with Pyrococcus furiosus DNA polymerase (Stratagene, La Jolla, CA), using the following amplification conditions: 94° for 30 sec, 58° for 30 sec, and 72° for 1 min for 35 cycles. The amplified p2y3 receptor gene was subcloned into theHpaI site of pLXSN, and clones harboring the insert in the correct orientation were identified by restriction mapping. Recombinant viral particles were produced in PA317 cells and used to infect 1321N1 cells as described previously (Comstock et al., 1997). 1321N1 cells expressing the rat P2Y6 receptor were produced in a similar manner (Nicholas et al., 1996), except that a single clone was expanded from the cell population and used in activity assays. Cells were selected with 1 mg/ml G418 in Dulbecco’s modified Eagle medium and were maintained in the same medium with 400 μg/ml G418.

    Measurement of [3H]inositol phosphate accumulation.

    Cells were plated in 24-well plates at 5 × 104 cells/well and were assayed after 3 days in culture. Inositol lipids were radiolabeled by overnight incubation with 0.4 μCi of myo-[3H]inositol/well, in 200 μl of inositol-free Dulbecco’s modified Eagle medium. No changes of medium were made after the addition of [3H]inositol. Drug challenges were initiated by addition of 50 μl of 5-fold concentrated agonists in 50 mm LiCl. After a 5-min incubation at 37°, the reactions were stopped by aspiration of the medium and addition of 0.5 ml of boiling 10 mm EDTA, pH 8.0. [3H]Inositol phosphates were isolated by chromatography on Dowex AG1-X8 resin, as described previously (Filtzet al., 1994; Lazarowski et al., 1995). All nucleoside diphosphates were treated with hexokinase, as described (Nicholas et al., 1996), to remove contaminating nucleoside triphosphates.

    Measurement of intracellular Ca2+ levels.

    1321N1 cells expressing either the turkey p2y3 receptor or the rat P2Y6 receptor were plated at low density on glass coverslips and assayed after 2–3 days in culture. On the day of the assay, the cells were incubated for 30 min with 0.5 μmfura-2/acetoxymethyl ester, washed, placed in a sealed recording chamber, and continuously superfused with Hanks’ buffered saline solution at a constant flow rate of 1.4 ml/min (Palmer et al., 1994). To initiate responses, cells were superfused for 30 sec with UTP and UDP (freshly purified by HPLC). Changes in intracellular Ca2+ levels were quantified by recording the fluorescence of 8–12 cells at 510 nm, after excitation at 340 and 380 nm. No more than 25 cells were in the visual field in any single experiment. The fluorescence ratio values from individual cells were averaged for each concentration and plotted versus time, and the area under the curve was determined by using Prism (GraphPad) software.

    Screening of human genomic libraries with a turkey p2y3 probe.

    Two genomic libraries were screened with a turkey p2y3 receptor probe, in an attempt to identify a human homologue of the p2y3 receptor. One of the libraries was purchased from Stratagene (a λ-fix library of placental DNA with insert sizes of 9–23 kilobases), and the other was constructed by Dr. John Lowe (University of Michigan, Ann Arbor, MI) (a λ-fix library of DNA isolated from peripheral blood lymphocytes, with insert sizes of 9–15 kilobases). For each screening, 1 × 106 phage were plated and transferred in duplicate to nylon filters. The filters were hybridized at 42° in 4.5× SSC (1× = 150 mm NaCl, 15 mm sodium citrate), 50% formamide, 1× Denhardt’s solution (1× = 0.02% Ficoll 400, 0.02% polyvinylpyrrolidone, and 0.02% bovine serum albumin), and 0.1% SDS, with a32P-labeled probe encompassing the entire coding sequence of the turkey p2y3 receptor. The filters were washed three times, for 15 min each, in 0.5× SSC/0.1% SDS at 50° and were apposed to film for 2–4 days. All plaques displaying hybridization on both sets of filters were isolated and plaque-purified. The identity of each positively hybridizing plaque was determined by a combination of high-stringency screening (wash conditions of 0.1× SSC/0.1% SDS at 70°) and PCR with P2Y receptor-specific primers.

    For Southern blotting, genomic DNA isolated from HeLa cells was digested with the appropriate restriction enzymes, separated on 0.7% agarose gels, and transferred to nylon membranes after denaturation and renaturation of the DNA. The blots were hybridized with either a p2y3 receptor probe or a rat P2Y6 receptor probe also encompassing the entire coding sequence. The blot hybridized with the p2y3 receptor probe was washed under low-stringency conditions, whereas the blot hybridized with the rat P2Y6 receptor probe was washed under high-stringency conditions.

    Previous SectionNext Section

    Results

    Direct comparison of the agonist selectivities of rat P2Y6 and turkey p2y3 receptors expressed in 1321N1 cells.

    The turkey homologue of the chick p2y3 receptor was amplified from genomic DNA using primers based on the chick sequence. The amino acid sequence of the turkey p2y3 receptor, like many other turkey signaling proteins, was nearly identical (97.6%) to that of its chick homologue, with eight amino acid differences between the two (GenBank accession number AF069555). Because the pharmacological selectivities and second messenger signaling properties of the chick p2y3 receptor and the rat P2Y6 receptor have not been directly compared, the turkey p2y3 and rat P2Y6 receptors were expressed in 1321N1 cells and assayed under identical conditions, as described in Experimental Procedures. As predicted from the results of Webb et al.(1996), who measured mobilization of intracellular Ca2+ in Jurkat cells, both UTP and UDP stimulated inositol phosphate accumulation in 1321N1 cells stably expressing the turkey p2y3 receptor (see below). Therefore, the avian p2y3 receptor, like the mammalian P2Y6 receptor, activates PLC.

    We assessed the capacities of a variety of nucleotides to activate both the turkey p2y3 receptor and the rat P2Y6receptor, to compare the agonist selectivities of these receptors (Figs. 1– 3, Table1). UDP was the most potent agonist at both the rat P2Y6 receptor and the turkey p2y3 receptor in promoting inositol phosphate accumulation (Fig. 1). The potent effects of UDP were not the result of the presence of contaminating UTP, because UDP (and other nucleoside diphosphates) was treated with hexokinase and glucose before the assays and during the incubations with the cells (Nicholas et al., 1996). 5-Bromo-UDP was equipotent with UDP and exhibited nearly identical potencies at both p2y3 and P2Y6 receptors (Fig.1). UTP was apparently a less potent full agonist, with nearly identical EC50 values for the turkey p2y3 and rat P2Y6 receptors. However, the agonist effects of UTP in this type of experiment are difficult to assess, because some or all of this effect could be the result of degradation of UTP to UDP, which is a potent agonist at both receptors.

    Figure 1
    View larger version:
    Figure 1

    Pharmacological selectivities of the turkey p2y3 and rat P2Y6 receptors for uridine nucleotides. Inositol phosphate accumulation was measured in 1321N1 cells expressing either the turkey p2y3 receptor (A) or the rat P2Y6 receptor (B), after a 5-min incubation with the indicated nucleotides in the presence of LiCl. Nucleoside diphosphates were pretreated with hexokinase and glucose as described previously (Nicholas et al., 1996). The data were normalized to the maximal effect of UDP in each experiment and represent results from at least three different experiments. The standard error of each value was always <10% of the mean. The values for basal and agonist-induced [3H]inositol phosphate accumulation were ∼600 and ∼2700 cpm, respectively, for p2y3 receptor-expressing 1321N1 cells and ∼900 and ∼3800 cpm, respectively, for P2Y6receptor-expressing 1321N1 cells. 5BrUDP, 5-bromo-UDP.

    View this table:
    Table 1

    EC50 values of nucleotides for stimulation of inositol phosphate accumulation by turkey p2y3 and rat P2Y6 receptors expressed in 1321N1 cells

    The capacity of UTP and UDP to stimulate intracellular Ca2+ mobilization was assessed under conditions that minimize or eliminate nucleotide breakdown. Assays were carried out with HPLC-purified nucleotides using continuously superfused cells present at low density. UTP was a full agonist at both receptors in measurements of Ca2+ mobilization (Fig. 2). The EC50 values of UDP and UTP determined for promotion of intracellular Ca2+ mobilization for the p2y3 receptor were 24 nm and 1.3 μm, respectively, and those for the P2Y6 receptor were 13 nm and 1.0 μm, respectively. These EC50 values were approximately 2-fold lower than the corresponding EC50 values determined for promotion of inositol phosphate accumulation (Table 1). The fact that the relative potencies of UTP and UDP determined with the two sets of assay conditions were the same suggests that significant amounts of UDP did not accumulate in the medium of 1321N1 cells during the 5-min inositol phosphate assays. Moreover, these data indicate that the selectivities of the turkey p2y3 and rat P2Y6receptors for uridine nucleotides are essentially identical.

    Figure 2
    View larger version:
    Figure 2

    Promotion of intracellular Ca2+mobilization by HPLC-purified UTP and UDP in 1321N1 cells expressing the turkey p2y3 receptor (A) or the rat P2Y6 receptor (B). Cells were plated on glass coverslips at low density and were loaded with fura-2/acetoxymethyl ester on the day of the experiment. The cells were placed in a sealed chamber under constant superfusion, and intracellular Ca2+ levels were measured in response to a 30-sec application of HPLC-purified nucleotides. The 340/380-nm ratios for 10–15 cells in a single optical field for each concentration of agonist were averaged and plotted versus time, to yield the area under the curve.

    In contrast to the similar effects of uridine nucleotides at the turkey p2y3 and rat P2Y6 receptors, adenine nucleotides were more potent at the p2y3 receptor than at the P2Y6 receptor (Fig. 3, Table 1). For example, whereas ADP was a relatively potent full agonist at the p2y3 receptor, it was nearly 20-fold less potent at the rat P2Y6receptor. Similarly, ATP was a low-potency full agonist at the turkey p2y3 receptor but had little effect at the rat P2Y6 receptor. 2-Methylthio-ADP was nearly equipotent with ADP at both receptors, whereas ADP-β-thiol was 15-fold less potent at the rat P2Y6 receptor than at the turkey p2y3 receptor (Fig. 3, Table 1).

    Figure 3
    View larger version:
    Figure 3

    Pharmacological selectivities of the turkey p2y3 and rat P2Y6 receptors for adenine nucleotides and nucleotide derivatives. Inositol phosphate accumulation was measured in 1321N1 cells expressing either the turkey p2y3 receptor (A) or the rat P2Y6 receptor (B), after a 5-min incubation with the nucleotides in the presence of LiCl. Nucleoside diphosphates were pretreated with hexokinase and glucose as described previously (Nicholas et al., 1996). The data were normalized to the maximal effect of UDP in each experiment and represent results from at least three different experiments. The standard error of each value was always <10% of the mean. 2MeSADP, 2-methylthio-ADP;ADPβS, ADP-β-thiol.

    Attempts to clone a human homologue of the avian p2y3 receptor.

    Unambiguous confirmation that the p2y3 receptor is a unique P2Y receptor subtype would follow from the cloning of its mammalian homologue. Therefore, we devised a strategy to identify a potential human homologue of the turkey p2y3 receptor, based on low-stringency screening of human genomic libraries with a p2y3 receptor probe. Genomic libraries were chosen for this purpose because several genome equivalents could be sampled in a single screening, no prior knowledge of tissue distribution was required, and the issue of clone representation in cDNA libraries could be avoided. We reasoned that, if a mammalian homologue of the avian p2y3 receptor exists, it would be more homologous to a turkey p2y3 probe than to a rat P2Y6 receptor probe. Therefore, hybridization and washing conditions were optimized for filters containing P2Y1, P2Y2, P2Y4, and P2Y6 receptor genomic bacteriophage λ clones (previously isolated from the leukocyte genomic library), using a turkey p2y3 receptor probe. This optimization of screening parameters identified conditions that ensured clear identification of human P2Y6 clones during library screening.

    Fifteen clones that hybridized to the turkey p2y3 receptor probe were isolated from two different human genomic libraries, and all 15 of these clones encoded P2Y receptors (Table2). The hybridization intensities of these clones fell into three classes: high intensity, medium intensity, and weak intensity. After plaque purification, the identity of each clone was determined both by high-stringency screening with human P2Y receptor probes and by PCR using P2Y receptor-specific primers. Ten of these clones encoded the P2Y6 receptor gene, and these clones corresponded to the clones that hybridized with the highest intensity to the p2y3 receptor probe (Table 2). Four clones that hybridized to the probe with medium intensity were shown to encode the P2Y2 receptor gene, and a single, weakly hybridizing clone encoded the P2Y4 receptor gene.

    View this table:
    Table 2

    Identities of clones isolated with the turkey p2y3 receptor probe

    Although this possibility is unlikely, it could be argued that clones encoding a potential human homologue of the avian p2y3 receptor were not adequately represented in either of the genomic libraries. To address this concern, we carried out Southern blot analysis of human DNA. Identical aliquots of DNA that had been digested with four different restriction enzymes were separated on agarose gels, blotted onto nylon filters, and screened with either a turkey p2y3 receptor probe at low stringency or a rat P2Y6 receptor probe at high stringency (Fig. 4). The rat P2Y6 receptor probe hybridized to a single fragment in each of the four lanes (Fig. 4, left). Notably, the p2y3 receptor probe hybridized with highest intensity to the same fragments as did the rat P2Y6 receptor probe, indicating that no other gene exists in the human genome that is more homologous to the turkey p2y3 receptor than the human P2Y6 receptor. An additional band, of lower intensity, was present in three of the four lanes of the blot probed at low stringency with the turkey p2y3 receptor probe (Fig. 4,right). Although the identities of these bands remain unknown, these same bands were observed in Southern blots probed with the rat P2Y6 receptor probe at low stringency.

    Figure 4
    View larger version:
    Figure 4

    Southern blots of human genomic DNA screened with either a turkey p2y3 receptor (right) or rat P2Y6 receptor (left) probe. Southern blots of human genomic DNA were prepared and hybridized with full-length probes derived from either the turkey p2y3 or rat P2Y6receptor. The blot hybridized with the rat P2Y6 receptor probe was washed at high stringency and the blot hybridized with the turkey p2y3 receptor probe was washed at low stringency, as described in Experimental Procedures. The extra bands observed in the control lanes of the blot hybridized with the rat P2Y6 receptor probe were likely the result of hybridization of the probe with vector sequences (i.e., the probe contained a small amount of vector DNA).

    Previous SectionNext Section

    Discussion

    Webb et al. (1996) reported the cloning and characterization of a chick P2Y receptor that is 65% identical to the rat P2Y6 receptor. We have cloned the turkey homologue (∼98% identical to the chick sequence) of the chick p2y3 receptor and expressed it in 1321N1 cells, to directly compare its pharmacological selectivity with that of the rat P2Y6 receptor. These studies show that the two receptors have very similar, but not identical, pharmacological selectivities. Both the turkey p2y3 and rat P2Y6receptors were activated most potently by UDP and much less potently by UTP. Similarly, 5-bromo-UDP was equipotent with UDP at both receptors. In contrast to the similar effects of uridine nucleotides, adenine nucleotides were more potent at the turkey p2y3 receptor than at the rat P2Y6 receptor. The pharmacological selectivity of the turkey p2y3 receptor for stimulation of inositol lipid hydrolysis in 1321N1 cells was very similar to that described for the chick p2y3 receptor for mobilization of intracellular Ca2+ in Jurkat cells but very different from the selectivity reported for the chick receptor expressed in X. laevis oocytes. The source of this difference in apparent agonist selectivity in these expression systems is not clear.

    The status of UTP as an agonist at the p2y3 and P2Y6 receptors also was assessed. The stimulatory activity observed during incubation with UTP potentially could have resulted entirely from breakdown of UTP to UDP by ecto-nucleotidases or from contamination of the UTP stocks with UDP. Therefore, we took advantage of a constant flow system for measurement of intracellular Ca2+ levels in cells plated at low density, to eliminate the contribution of ecto-nucleotidase activity during determination of nucleotide selectivities. HPLC-purified UTP was a full agonist, with ∼50-fold lower potency than UDP, in 1321N1 cells expressing either the turkey p2y3 or rat P2Y6receptor.

    We reported previously that ADP was a partial agonist at the rat P2Y6 receptor (Nicholas et al., 1996), whereas in this study it was apparently a full agonist. The agonist effects of ADP reported here may be the result of higher receptor expression levels in the clonal cell line used in this study, compared with the population of cells assayed previously. Higher receptor densities could result in full-agonist effects of partial agonists and in apparent increases in the potencies of full agonists (Hardenet al., 1997). This possibility is supported by the nearly 10-fold lower EC50 of UDP for stimulation of inositol lipid hydrolysis in the clonal line of P2Y6 receptor-expressing cells, compared with the value previously observed with the cell population.

    Webb et al. (1996) proposed that the avian p2y3 receptor is a novel P2Y receptor subtype. This conclusion was based on the assumption that the 65% sequence identity of the chick p2y3 receptor to the rat P2Y6 receptor was too low for these receptors to be species homologues. However, this percent identity is much greater that the percent identity (∼40%) of the p2y3 receptor to other mammalian P2Y receptors. Furthermore, the percent identity between the two receptors increases to 74% when only the putative membrane-spanning regions are considered. The avian p2y3 receptor and mammalian P2Y6 receptor have similar pharmacological selectivities, and we observed no evidence for the existence of a gene in the human genome that is more homologous to the turkey p2y3 receptor than the human P2Y6receptor. The most parsimonious interpretation of these results is that the avian p2y3 and human P2Y6 receptors are species homologues.

    There are parallels between the P2Y and β-AR subtypes in both birds and mammals. Turkeys have three known β-AR subtypes. The turkey β2-AR is 85% identical to its mammalian orthologue and exhibits nearly identical pharmacological selectivity (Del Toro F and Nicholas RA, manuscript in preparation), the turkey β1-AR is 68% identical to the mammalian β1-AR and has similar but not identical pharmacological selectivity (Minneman et al., 1980; Yardenet al., 1986), and the turkey β4C-AR is approximately 50% identical to all known β-AR subtypes and has unique pharmacological selectivity (Chen et al., 1994). No mammalian homologue of the β4C-AR has yet been identified. A nearly identical comparison can be made for avian and mammalian P2Y receptors. Thus, the avian and mammalian P2Y1 receptors are 85% identical and exhibit nearly identical pharmacological selectivities (Schachter et al., 1996), the avian p2y3 and mammalian P2Y6 receptors are 65% identical and exhibit similar but not identical pharmacological selectivities, and a newly identified avian P2Y receptor (Boyer et al., 1997) has 40–50% identity to the four mammalian P2Y receptor subtypes and pharmacological selectivity similar to that of the P2Y2 receptor. As with the β4C-AR, no mammalian homologue for this avian P2Y receptor has been identified.

    Previous SectionNext Section

    Footnotes

    • Send reprint requests to: Dr. Robert Nicholas, University of North Carolina at Chapel Hill, Department of Pharmacology, CB 7365, Chapel Hill, NC 27599-7365. E-mail:nicholas{at}med.unc.edu

    • ↵1 In accordance with the recommendations of the International Union of Pharmacology Nomenclature Committee (Vanhoutte et al., 1996), we have used the designation p2y3 for this P2Y receptor because it is not from a mammalian species and no mammalian homologue has been identified.

    • This work was supported by National Institutes of Health Grant GM38213. R.A.N. is an Established Investigator of the American Heart Association.

    • Abbreviations:
      PLC
      phospholipase C-β
      SDS
      sodium dodecyl sulfate
      SSC
      standard saline citrate
      PCR
      polymerase chain reaction
      HPLC
      high-performance liquid chromatography
      AR
      adrenergic receptor
      • Received May 1, 1998.
      • Accepted June 5, 1998.
    Previous Section
     

    References

    1. ↵
      1. Boyer JL,
      2. Waldo GL,
      3. Harden TK
      (1997) Molecular cloning and expression of an avian G protein-coupled P2Y receptor. Mol Pharmacol 52:928–934.
      Abstract/FREE Full Text
    2. ↵
      1. Chen XH,
      2. Harden TK,
      3. Nicholas RA
      (1994) Molecular cloning and characterization of a novel β-adrenergic receptor. J Biol Chem 269:24810–24819.
      Abstract/FREE Full Text
    3. ↵
      1. Communi D,
      2. Govaerts C,
      3. Parmentier M,
      4. Boeynaems JM
      (1997) Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem 272:31969–31973.
      Abstract/FREE Full Text
    4. ↵
      1. Communi D,
      2. Motte S,
      3. Boeynaems JM,
      4. Pirotton S
      (1996) Pharmacological characterization of the human P2Y4 receptor. Eur J Pharmacol 317:383–389.
      CrossRefMedlineWeb of Science
    5. ↵
      1. Comstock KE,
      2. Watson NF,
      3. Olsen JC
      (1997) Design of retroviral expression vectors. Methods Mol Biol 62:207–222.
      Medline
    6. ↵
      1. Jacobson KA,
      2. Jarvis MF
      1. Filtz TA,
      2. Harden TK,
      3. Nicholas RA
      (1997) Structure, pharmacological selectivity, and second messenger signaling properties of G protein-coupled P2-purinergic receptors. in Purinergic Approaches in Experimental Therapeutics, eds Jacobson KA, Jarvis MF (John Wiley and Sons, New York), pp 39–53.
    7. ↵
      1. Filtz TA,
      2. Li Q,
      3. Boyer JL,
      4. Nicholas RA,
      5. Harden TK
      (1994) Expression of a cloned P2Y-purinergic receptor that couples to phospholipase C. Mol Pharmacol 46:8–14.
      Abstract
    8. ↵
      1. Harden TK,
      2. Boyer JL,
      3. Nicholas RA
      (1995) P2-purinergic receptors: subtype-associated signaling responses and structure. Annu Rev Pharmacol Toxicol 35:541–579.
      CrossRefMedlineWeb of Science
    9. ↵
      1. Leff P
      1. Harden TK,
      2. Dougherty R,
      3. Boyer JL
      (1997) Drug analysis based on signaling responses to G protein-coupled receptors. in Receptor-Based Drug Design, ed Leff P (Marcel Dekker, New York), pp 79–105.
    10. ↵
      1. Hechler B,
      2. Vigne P,
      3. Leon C,
      4. Breittmayer JP,
      5. Gachet C,
      6. Frelin C
      (1998) ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol 53:727–733.
      Abstract/FREE Full Text
    11. ↵
      1. Henderson DJ,
      2. Elliot DG,
      3. Smith GM,
      4. Webb TE,
      5. Dainty IA
      (1995) Cloning and characterisation of a bovine P2Y receptor. Biochem Biophys Res Commun 212:648–656.
      CrossRefMedlineWeb of Science
    12. ↵
      1. Lazarowski ER,
      2. Homolya L,
      3. Boucher RC,
      4. Harden TK
      (1997) Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation. J Biol Chem 272:24348–24354.
      Abstract/FREE Full Text
    13. ↵
      1. Lazarowski ER,
      2. Watt WC,
      3. Stutts MJ,
      4. Boucher RC,
      5. Harden TK
      (1995) Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol 116:1619–1627.
      MedlineWeb of Science
    14. ↵
      1. Lazarowski ER,
      2. Watt WC,
      3. Stutts MJ,
      4. Brown HA,
      5. Boucher RC,
      6. Harden TK
      (1996) Enzymatic synthesis of UTPγS, a potent hydrolysis resistant agonist of P2U-purinoceptors. Br J Pharmacol 117:203–209.
      MedlineWeb of Science
    15. ↵
      1. Leon C,
      2. Hechler B,
      3. Vial C,
      4. Leray C,
      5. Cazenave JP,
      6. Gachet C
      (1997) The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 403:26–30.
      CrossRefMedlineWeb of Science
    16. ↵
      1. Minneman KP,
      2. Weiland GA,
      3. Molinoff PB
      (1980) A comparison of the β-adrenergic receptor of the turkey erythrocyte with mammalian β1 and β2 receptors. Mol Pharmacol 17:1–7.
      Abstract/FREE Full Text
    17. ↵
      1. Nguyen T,
      2. Erb L,
      3. Weisman GA,
      4. Marchese A,
      5. Heng HH,
      6. Garrad RC,
      7. George SR,
      8. Turner JT,
      9. O’Dowd BF
      (1995) Cloning, expression and chromosomal localization of the human uridine nucleotide receptor gene. J Biol Chem 270:30845–30848.
      Abstract/FREE Full Text
    18. ↵
      1. Nicholas RA,
      2. Watt WC,
      3. Lazarowski ER,
      4. Li Q,
      5. Harden TK
      (1996) Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. Mol Pharmacol 50:224–229.
      Abstract
    19. ↵
      1. Palmer RK,
      2. Yule DI,
      3. McEwen EL,
      4. Williams JA,
      5. Fisher SK
      (1994) Agonist-specific calcium signaling and phosphoinositide hydrolysis in human SK-N-MCIXC neuroepithelioma cells. J Neurochem 63:2099–2107.
      Medline
    20. ↵
      1. Parr CE,
      2. Sullivan DM,
      3. Paradiso AM,
      4. Lazarowski ER,
      5. Burch LH,
      6. Olsen JC,
      7. Erb L,
      8. Weisman GA,
      9. Boucher RC,
      10. Turner JT
      (1994) Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc Natl Acad Sci USA 91:3275–3279.
      Abstract/FREE Full Text
    21. ↵
      1. Schachter JB,
      2. Li Q,
      3. Boyer JL,
      4. Nicholas RA,
      5. Harden TK
      (1996) Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinergic receptor. Br J Pharmacol 118:167–173.
      MedlineWeb of Science
    22. ↵
      1. Vanhoutte PM,
      2. Humphrey PAA,
      3. Spedding M
      (1996) X. International Union of Pharmacology recommendations for nomenclature of new receptor subtypes. Pharmacol Rev 48:1–2.
      Medline
    23. ↵
      1. Webb TE,
      2. Henderson D,
      3. King BF,
      4. Wang S,
      5. Simon J,
      6. Bateson AN,
      7. Burnstock G,
      8. Barnard EA
      (1996) A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates. Mol Pharmacol 50:258–265.
      Abstract
    24. ↵
      1. Yarden Y,
      2. Rodriguez H,
      3. Wong SK-F,
      4. Brandt DR,
      5. May DC,
      6. Burnier J,
      7. Harkins RN,
      8. Chen EY,
      9. Ramachandran J,
      10. Ullrich A,
      11. Ross EM
      (1986) The avian β-adrenergic receptor: primary structure and membrane topology. Proc Natl Acad Sci USA 83:6795–6799.
      Abstract/FREE Full Text
    « Previous | Next Article »Table of Contents

    This Article

    1. Molecular Pharmacology September 1, 1998 vol. 54 no. 3 541-546
    1. AbstractFree
    2. » Full Text
    3. Full Text (PDF)

    Classifications

    Responses

    1. Submit a response
    2. No responses published

    Navigate This Article

    Current Issue

    1. November 2009, 76 (5)
    1. Current Issue
    1. Alert me to new issues of Molecular Pharmacology